CA-NETAPP
15.11.2021 14:02:11 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, announced the extension of its partnership with the Ducati Corse motorcycle racing team at the completion of the 2021 MotoGP World Championship race in Valencia, Spain. For the next two years, NetApp will continue to help advance Ducati’s performance in the MotoGP World Championship, the world’s most prestigious motorcycle racing competition.
The collaboration between Ducati (part of the Volkswagen Group), through its Ducati Corse division, and NetApp began in 2018 in a bid to maximize the use of data to improve performance within the world of racing. NetApp and Ducati are expanding their work together to accelerate digital transformation by:
- Optimizing 3D product design in complex development projects by implementing a new virtual desktop environment, allowing engineers to collaborate efficiently all over the world. As part of this improvement, engineers and developers can securely leverage and archive any project data, using the rich functionalities of NetApp StorageGRID object storage.
- Automating the racing team’s data workflow before, during and after the race. Engineers can support their team’s success, both remotely and on-site to maximize the power of information for the win.
- Supporting the overall evolution of the information technology strategy through collaboration between Ducati and the Professional Services teams at NetApp.
“We are delighted to build on the collaboration with NetApp, which has developed well over the past four years,” said Luigi Dall'Igna, General Manager at Ducati Corse. “We look forward to working together to continue to optimize our performance with the limitless possibilities that the power of data can bring to the motorbike racing world.”
“Leading a winning team requires exploring new ways to succeed and finding any edge to beat the competition,” said Cesar Cernuda, President at NetApp. “Our partnership and momentum with Ducati Corse are thriving and the team secured three of the top five placements in world standings this year. We are proud to support the ongoing digital transformation of Ducati into a winning, data-driven company.”
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
About Ducati
Founded in 1926, since 1946 Ducati has been manufacturing sport-inspired motorcycles characterised by high-performance engines, innovative design and cutting-edge technology. Ducati factory is located in Bologna’s Borgo Panigale district. The model range covers several market segments with the following families: Diavel, XDiavel, Hypermotard, Monster, Multistrada, SuperSport, Panigale and Streetfighter. In 2015, Ducati presented the Ducati Scrambler: a new brand made of bikes, accessories and apparel that that stands out for its creativity and self-expression. In 2020 Ducati unveiled the Multistrada V4, the world's first motorcycle equipped with front and rear radar, which with its technology marks a new milestone for the world of two wheels. Ducati iconic motorcycles, together with an extensive range of bike accessories and technical and lifestyle apparel, are distributed in 90 countries worldwide. In 2020 Ducati delivered 48,042 bikes to customers. Ducati competes in both MotoGP and Superbike World Championships. The Company has been racing in the MotoGP category since 2003 and has won the Constructors' World Title in 2020 and 2021. Furthermore, Ducati was World Champion in the 2007 season, winning both Constructors' and Riders' Title. In Superbike, Ducati has won 17 Manufacturer's Titles and 14 Rider's Titles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom